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Sleep disturbance is common in dialysis patients and is
associated with the development of enhanced inflammatory
responses. Cognitive-behavioral therapy is effective for sleep
disturbance and reduces inflammation experienced by
peritoneal dialysis patients; however, this has not been
studied in hemodialysis patients. To determine whether
alleviation of sleep disturbance in hemodialysis patients also
leads to less inflammation, we conducted a randomized
controlled interventional study of 72 sleep-disturbed
hemodialysis patients. Within this patient cohort, 37 received
tri-weekly cognitive-behavioral therapy lasting 6 weeks and
the remaining 35, who received sleep hygiene education,
served as controls. The adjusted post-trial primary outcome
scores of the Pittsburgh Sleep Quality Index, the Fatigue
Severity Scale, the Beck Depression Inventory, and the
Beck Anxiety Inventory were all significantly improved from
baseline by therapy compared with the control group. The
post-trial secondary outcomes of high-sensitive C-reactive
protein, IL-18, and oxidized low-density lipoprotein levels
significantly declined with cognitive-behavioral therapy in
comparison with the control group. Thus, our results suggest
that cognitive-behavioral therapy is effective for correcting
disorganized sleep patterns, and for reducing inflammation
and oxidative stress in hemodialysis patients.
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Sleep disturbance is common among patients with end-stage
renal disease, and it significantly affects quality of life,
overall morbidity, hospitalization, and mortality.1,2 In the
general population, subjects with sleep disturbance or healthy
volunteers experiencing sleep deprivation have enhanced
inflammatory responses,3–5 and some inflammatory cyto-
kines, especially the interleukin-1 (IL-1) family, have critical
roles in the regulation of physiological sleep.6,7 In our
previous research, we demonstrated that hemodialysis (HD)
patients with sleep problems have higher IL-18 and high-
sensitive C-reactive protein (hs-CRP) levels.8,9 Moreover,
treatment for sleep disturbance partially eliminates the
plethora of inflammatory cytokines in peritoneal dialysis
patients.10 All of this evidence implies a connection between
sleep disturbance and inflammation. However, whether
effective alleviation of sleep disturbance in HD patients also
leads to a less inflammatory milieu has not yet been
investigated.
Augmented oxidative stress is generally found in HD
patients, and it leads to cardiovascular complications.11–13
Oxidized low-density lipoprotein (oxLDL) is a main
oxidative stress marker closely associated with inflammatory
response, and it predicts cardiovascular mortality in HD
patients.14,15 Interestingly, in an animal model, sleep
deprivation led to an enhanced burden of oxidative stress,
and sleep recovery restored the depletion of anti-oxidants in
mice.16 In humans, subjects with obstructive sleep apnea
(OSA), another type of sleep disturbance prevalent in dialysis
patients,17 suffer from advanced oxidative stress.18–20 Sleep
disturbances other than OSA may also be associated with
changes in oxidative stress in dialysis patients.
Cognitive-behavioral therapy (CBT), the most widely used
psychological intervention for insomnia, has been proven to
be effective for chronic insomnia.21–23 In our pilot small-scale
study, we confirmed the efficacy of CBT on sleep disturbance
and showed the beneficial effects on inflammatory burden in
peritoneal dialysis patients.10 In a recently published article,
CBTwas reported to be effective in treating HD patients with
major depression.24 As is already well known, subjects with
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depression have higher oxidative stress and inflammation.25
However, the efficacy of CBT on treating sleep disturbance,
depressive symptoms, and anxiety in prevalent HD patients
without other psychiatric disorders has not yet been investi-
gated. In addition, whether CBT has additional impact on
inflammatory cytokines and oxidative stress while reforming
disorganized sleep patterns and modifying depression in this
population remains unknown.
In this prospective randomized control study, we investi-
gated the efficacy of CBT for treating HD patients with sleep
disturbance. In addition, we aimed to observe changes in
inflammatory cytokines and oxidative stress marker during
CBT. The purpose was to validate the therapeutic efficacy of
CBT for sleep disorders and other psychological aspects, such
as severity of fatigue, depressive mood, and anxiety burden.
We also investigated its potential influence on inflammation
and oxidative stress, the detrimental factors of survival and
cardiovascular complications, in prevalent HD patients.
RESULTS
Baseline participant characteristics
A total of 72 patients (42 women and 30 men) with a mean
age of 58±11 years were enrolled in the trial. Baseline
demographic characteristics, dialysis parameters, and labora-
tory data are summarized in Table 1. The baseline charac-
teristics and clinical parameters of participants in the two
groups were similar (all P40.05).
Numbers analyzed
Figure 1 shows recruitment numbers, exclusions, refusal, and
dropouts throughout the study. We did not complement
a further eight participants before the intervention period.
Therefore, the pre- and post-trial data of all of the participants
(N¼ 72) were analyzed by ‘per-protocol’ analysis.
Baseline primary and secondary outcomes of participants
The outcomes are summarized in Table 2. All of the baseline
measurements of primary and secondary outcomes were
similar in participants of both groups (all P40.05), except
that participants in the CBT group had longer sleep latency.
Intervention effects on primary outcomes
A total of 32 participants (86.5%) in the CBT group had a
decline in global Pittsburgh Sleep Quality Index (PSQI)
compared with 10 (28.6%) in the control group (Po0.001).
A significant improvement in global PSQI was demonstrated
in the CBT group (Tables 2 and 3). Furthermore, participants
in the CBT group had a prolonged sleep duration and
increased sleep efficiency after the 6-week trial (Table 3).
Intervention effects on secondary outcome measures
The effects of intervention on secondary outcomes are
presented in Tables 2 and 4. In the CBT group, there were
pre- to post-intervention declines in serum levels of hs-CRP,
IL-1b, IL-18, and oxLDL. However, in the control group,
serum levels of hs-CRP, IL-1b, IL-18, and oxLDL were all
increased after the 6-week trial (Table 2). Comparing the
changes of secondary outcomes during the 6-week trial,
participants in the CBT group had a much larger decline in
hs-CRP, IL-18, and oxLDL levels after the trial than did those
in the control group (Table 4).
Intervention effects on other assessments
A total of 29 participants (78.4%) in the CBT group had a
decline in the Fatigue Severity Scale (FSS) scores compared
with 17 (48.6%) in the control group (P¼ 0.007); 26 (70.3%)
had a decline in the Beck Depression Inventory (BDI) scores
in the CBT group compared with 15 (42.9%) in the control
group (P¼ 0.014), and 23 (62.2%) had a decline in the
Beck Anxiety Inventory (BAI) scores in the CBT group
compared with 15 (42.9%) in the control group (P¼ 0.073).
Improvements in FSS and BAI, but not in BDI, were
demonstrated in the CBT group (Table 2). Participants in
the CBT group experienced significant improvements in
FSS, BDI, and BAI after adjusting for baseline FSS, BDI, and
BAI (Table 3).
Compliance and adverse events
There were no absentees during the intervention period.
No adverse events were reported during the intervention.
DISCUSSION
In this randomized control study, we assessed the efficacy of
a 6-week trial of CBT for HD patients with sleep disturbance
and its potential effects on inflammation and oxidative stress.
The main results provided novel evidence that CBT is effec-
tive in helping HD patients with sleep disturbance to improve
sleep quality, severity of fatigue, and decrease depressive
emotion and anxiety as evaluated by questionnaires. In addi-
tion, treating with CBT may also alter inflammatory bio-
markers and oxidative stress in this population.
CBT has great efficacy in treating subjects with insomnia
in various populations.10,21–23,26 As compared with previous
investigations,22,23 our results showed good and comparable
efficacy on sleep disturbance; B80% of our HD patients
experienced favorable changes in PSQI, as well as prolonged
sleep duration and enhanced sleep efficiency (Table 3).
Post-trial PSQI was still within the sleep pathology range
(45, Table 3); however, improvements in global PSQI after
intervention were statistically significant and comparable
with other clinical trials.27,28 This might be due in part to
the relatively short treatment period of CBT in this trial.
In previous studies, extended CBT treatment periods
(X6 months) proved augmented achievement in better sleep
quality.23,29 Nevertheless, the favorable changes in total sleep
duration and sleep efficiency in our study (Table 3) suggested
that CBT is also clinically effective rather than only statis-
tically effective in total scores of self-reported questionnaires.
In addition, compared with similar 6-week CBT trials,21,22,29
improvements in total sleep time and sleep efficiency
were approximately equal. A recent investigation conducted
by Duarte et al.24 demonstrated that 3-month (12-weekly
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sessions) CBT was effective in treating depression and
improving sleep quality measured by the sleep dimension
of The Kidney Disease and Quality of Life-Short Form in HD
patients with major depression. Our participants did not
have major depression and the severity of depressive
symptoms was much lower than their participants
(BDI¼ 15–16, Table 2). In our results, participants in the
CBT group experienced B13% decline in BDI; however,
those in the control group did not (Table 3). This
improvement in depressive symptoms may be associated
with changes in items regarding sleep quality in the somatic
domain of BDI. Although there were major differences in
study populations, both studies revealed that CBT helped HD
patients overcome depressive symptoms and modify sleep
quality. In addition, CBT alleviated the severity of anxiety
(13% decline in BAI, Table 3) in HD patients, another novel
finding in this investigation, and this is consistent with the
results of a recent study involving non-dialysis elderly
patients with anxiety disorder.30
In our previous studies, we found that higher IL-18
and hs-CRP levels were associated with poor sleep quality
in peritoneal dialysis and HD patients.8,9 IL-18 regulates
T-helper type 1 responses, and dysregulation of T-helper type
1 cells may lead to sleep disturbances.31 Therefore, beyond
the psychological treatment effect, we propose that the
association between CBT and favorable changes in inflam-
mation in dialysis patients may be potentially linked to the
physiological mechanism of CBTon sleep disturbance. In this
study, we similarly demonstrated a decline in hs-CRP and
IL-18 levels in participants of the CBT group, but not in the
control group. We cannot conclude that CBT caused the
beneficial effect on inflammatory cytokines directly or
secondary to the bonus of relieving sleep disturbance;
however, such evidence further strengthens the theory that
inflammation is involved in the potential mechanism of
CBT with regard to the physiological aspect(s).
The association of sleep deprivation with enhanced
oxidative stress has been demonstrated in many animal
Table 1 | Baseline characteristics of the study patients
All patients (N=72) CBT group (N=37) Control group (N=35) P-value
Age (years) 58 (10) 57 (9) 59 (11) 0.491
Gender (M/F) 30/42 17/20 13/22 0.373
HD vintage (years) 5.9 (4.2) 5.8 (4.0) 6.0 (5.0) 0.532
BMI 23.4 (3.5) 23.3 (3.6) 23.4 (3.0) 0.872
DM (%) 33 32.4 34.3 0.602
HTN (%) 60 59.4 62.0 0.524
Education (%) 0.082
Illiterate 2.5 2.5 2.5
Primary school 41.25 47.5 35
Middle school 16.25 5 27.5
High school 31.25 37.5 25
College 8.75 7.5 10
Employed (%) 56.3 62.5 50 0.260
Previous use of hypnotics (%) 69.4 67.6 71.4 0.362
No. of prescribed hypnotics (person) 0.92 (0.88) 0.88 (0.8) 0.94 (0.95) 0.718
One hypnotic 32 21 11
Two hypnotics 13 4 9
Three hypnotics 5 2 3
Use of statins (%) 34.7 35.1 34.3 0.661
Use of ACEi/ARB (%) 26.4 27.0 25.7 0.654
Laboratory data
Kt/Vurea 1.56 (0.18) 1.55 (0.29) 1.57 (0.50) 0.351
BUN (mg/dl) 71 (18) 71 (19) 72 (18) 0.873
Creatinine (mg/dl) 10.8 (1.9) 10.9 (2.0) 10.7 (1.8) 0.441
Hemoglobin (g/dl) 11.3 (1.2) 11.0 (1.3) 11.4 (1.4) 0.113
Albumin (g/dl) 4.2 (0.3) 4.2 (0.3) 4.3 (0.3) 0.589
nPCR (g/Kg/d) 1.13 (0.25) 1.13 (0.22) 1.13 (0.27) 0.626
Potassium 4.6 (0.7) 4.6 (0.6) 4.7 (0.7) 0.433
Calcium (mg/dl) 9.3 (0.8) 9.3 (0.7) 9.3 (0.5) 0.736
Phosphorus (mg/dl) 5.2 (1.5) 5.3 (1.3) 5.2 (1.7) 0.597
CaXP 49 (13) 49 (13) 49 (14) 0.988
iPTH (pg/ml) 321 (285) 312 (179) 326 (192) 0.364
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CaXP, calcium phosphorus
product; CBT, cognitive-behavioral therapy; DM, diabetes mellitus; HD, hemodialysis; HTN, hypertension; iPTH, intact parathyroid hormone; nPCR, normalized protein
catabolic rate.
Data are expressed as mean (s.d.).
Kidney International (2011) 80, 415–422 417
H-Y Chen et al: CBT for HD patients with insomnia o r ig ina l a r t i c l e
studies;5,16,32 however, in humans, this connection has not
been proven. Only subjects with OSA have enhanced
oxidative stress and inflammation.18–20 In this trial, the pre-
trial oxLDL levels of our participants were similar to those
published in previous studies performed on HD patients,33,34
and the post-trial oxLDL levels declined in the CBT group,
but deteriorated in the control group after the 6-week trial.
A possible explanation for changes in oxLDL during the
trial may be the association between oxidative stress and
inflammation in HD patients.35 Therefore, changes in oxLDL
are possibly due to concurrent changes in inflammatory
markers occurring after CBT. On the other hand, subjects
with sleep disturbance may present with mild and often
unrecognized OSA; 16–30% of dialysis patients who have
OSA simply present as sleep disturbance,17 and CBT is
effective in treating the sleep complaints of patients with
OSA.36 Potentially, some of our participants had mild OSA
and suffered from higher oxidative stress, which was
alleviated after their sleep disturbance was improved by
CBT. However, as we did not perform polysomnographies in
this trial, we could not confirm this suspicion. The reason
why insomnious HD patients have a decline in oxLDL levels
after CBT needs further investigation.
The significant strengths of this study include its
randomized control design, careful selection, and diagnosis
of patients, breadth, and novelty of outcome assessment,
good treatment integrity, low attrition (7.5%) in the CBT
group, and significant improvement in primary and second-
ary outcomes. However, this study has limitations. First, we
lacked a long-term follow-up period to evaluate the effects
on secondary outcomes. The long-term effects of CBT on
sleep disturbance, major depression, and anxiety have been
confirmed in previous studies;21–23,29 however, the long-term
beneficial effects of CBT on inflammatory cytokines and
oxidative stress need further investigation to clarify our
findings. Second, 67.6% of participants in the CBT group and
71.4% in the control group used fixed-dose hypnotics
concurrently during the trial, and 6 participants in the CBT
group used 42 hypnotics. The beneficial effects, both on
primary and secondary outcomes, in this study, should be
recognized as the results of combining CBT and low-dose
hypnotics. In a recent randomized control study, both
CBT alone or combined with sleep medication effectively
improved quality of sleep.29 Therefore, our results strengthen
the add-on effect of CBT for HD patients with sleep
disturbance who are chronically dependent on hypnotics
with limited effects. Third, as OSA is prevalent in dialysis
patients and is associated with the burden of oxidative stress,
it would have been rational to perform polysomnography to
determine OSA in our insomnious participants. We only
Assessed for eligibility (n=368) Excluded (n =288) 
PSQI ≤5 (n =200) 
  Not meeting other inclusion 
criteria (n =84) 
History of sleep disturbance for 
< 6 months (n =30) 
With active medical conditions 
(n =33)
With active psychiatric 
conditions (n =15) 
Documented symptoms of OSA
and restless legs syndrome 
(n =6)
  Refused to participate (n =4) 
Analyzed (n =37) 
Excluded from analysis (n =0)
Lost to follow-up (n =0) 
Discontinued intervention (n =0)
Allocated to CBT group (n =40)
Refused to participate after 
randomization and withdrew 
informed consents (n =3) 
Lost to follow-up (n =0) 
Discontinued intervention (n =0)
Allocated to control group (n =40)
Refused to participate after 
randomization and withdrew 
informed consent (n =5) 
Analyzed (n =35) 
Excluded from analysis (n =0)
Allocation
Analysis
Follow-up
Enrollment
Randomized
(n =80)
Received CBT therapy (n =37)
Received control group monitoring
(n =35)
Intervention
period
Figure 1 | Study flow diagram. CBT, cognitive-behavioral therapy; OSA, obstructive sleep apnea; PSQI, Pittsburgh Sleep Quality Index.
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used the Epworth Sleepiness Scale to rule out OSA during
enrollment screening; however, the extent and location of
polysomnography for diagnosis of OSA is still the subject of
considerable debate.17 Therefore, we did not perform
polysomnography and tried to control for other influential
factors of oxidative stress such as dialyzer membrane
material, water purity, and contents of dialysate, under
similar stable conditions to minimize any unexpected impact
on oxidative stress beyond sleep disturbance and inflamma-
tion in this investigation.
In conclusion, in this randomized control study, we
demonstrated the favorable effects of CBT, in combination
with fixed doses of hypnotics, for sleep disturbance, fatigue,
relief of depressive mood, and anxiety in HD patients
based on self-reported evaluations, including PSQI, FSS, BDI,
and BAI. Our results also strengthen the linkage between
CBT and the beneficial changes in inflammatory cytokines
and oxidative stress in HD patients. Further investigations are
necessary to explore the potential underlying mechanisms.
MATERIALS AND METHODS
Participants
This was a randomized, controlled, prospective, interventional trial
of patients undergoing maintenance HD who had chronic sleep
disturbances. Sleep disturbances were defined as: (1) difficulties
initiating and maintaining sleep or (2) early morning awakenings
with inability to return to sleep, which satisfied the criteria for
insomnia in the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition. Other inclusion criteria included: (1)
subjects who had a PSQI score of 45 during screening of
enrollment; (2) age X18 years; (3) a history of sleep disturbance
for 46 months; and (4) subjects without active medical and
psychiatric conditions and other documented symptoms of OSA
(defined as Epworth Sleepiness Scale410 or typical symptoms) and
periodic limb movement disorders, such as restless legs syndrome.
All of the subjects (N¼ 368, at the time of enrollment screening)
undergoing maintenance HD received PSQI for screening of sleep
Table 2 | Baseline and post-trial comparisons of treatment groups between all outcome measures
CBT group (N=37) Control group (N=35)
CBT vs control
(pre-trial)
CBT vs control
(post-trial)
Measures Baseline 6 Weeks P-value Baseline 6 Weeks P-value P-value P-value
Primary outcomes
PSQI 13.4 (3.5) 9.9 (3.7) o0.001 12.2 (3.0) 11.6 (3.6) 0.036 0.181 0.04
Sleep duration (hours) 5.0 (1.6) 5.8 (1.5) o0.001 5.4 (1.4) 5.7 (1.6) 0.068 0.357 0.511
Sleep latency (minutes) 53.0 (30.1) 35.1 (26.1) o0.001 35.8 (29.0) 35.3 (28.2) 0.957 0.009 0.984
Sleep efficiency (%) 71.3 (18.2) 86.0 (15.9) o0.001 74.4 (17.7) 78.1 (17.8) 0.11 0.498 0.04
Secondary outcomes
Inflammatory markers
hs-CRP (mg/l) 2.4 (1.0, 5.7) 1.6 (0.7, 3.7) 0.002 2.8 (1.0, 5.8) 2.8 (1.2, 6.8) 0.283 0.973 0.114
IL-1b (pg/ml) 1.41 (0.94, 2.5) 1.04 (0.8, 2.96) 0.068 1.34 (0.77, 3.04) 1.35 (0.78, 2.94) 0.763 0.610 0.874
IL-18 (pg/ml) 379.0 (313.5, 435.6) 345.0 (244.3, 422.7) 0.022 369.8 (271.9, 428) 378.1 (299, 478) 0.054 0.527 0.085
oxLDL (Units/l) 42.8 (32.7, 60.9) 40.7 (30.9, 59.5) 0.013 46.7 (40.3, 55.5) 63.1 (49.8, 76.7) 0.001 0.403 o0.001
Other assessments
FSS 4.7 (1.2) 3.9 (1.5) o0.001 4.1 (1.0) 4.2 (1.8) 0.928 0.145 0.691
BDI 16.8 (8.8) 13.8 (11.5) 0.102 15.7 (13.2) 16.1 (14.2) 0.625 0.598 0.428
BAI 16.0 (10.2) 13.2 (11.4) 0.045 14.3 (11.0) 16.3 (13.2) 0.131 0.332 0.273
Abbreviations: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CBT, cognitive-behavioral therapy; FSS, Fatigue Severity Scale; hs-CRP, high-sensitive C-reactive
protein; IL-1b, interleukin 1 beta; IL-18, interleukin 18; oxLDL, oxidized low-density lipoprotein; PSQI, Pittsburgh Sleep Quality Index.
Data are expressed as mean (s.d.) or median (quartiles).
Table 3 | Adjusted results for post-intervention comparisons
Adjusted
post-intervention
mean (s.e.)
Measures
Adjusted
baseline mean
CBT
group
Control
group P-value
Primary outcomes
PSQI 13.2 9.6 (0.5) 11.8 (0.5) 0.001
Sleep duration (hours) 5.0 5.9 (1.5) 5.6 (1.6) 0.009
Sleep latency (minutes) 44.2 35.4 (26.2) 35.2 (26.3) 0.072
Sleep efficiency (%) 72.3 85.8 (16) 78.2 (17.8) 0.004
Other assessments
FSS 4.4 3.9 (1.5) 4.2 (1.8) 0.043
BDI 15.8 13.8 (11.3) 16.1 (14.0) 0.022
BAI 15.1 13.2 (11.4) 16.3 (13.2) 0.025
Abbreviations: ANCOVA, analysis of covariance; BAI, Beck Anxiety Inventory; BDI,
Beck Depression Inventory; CBT, cognitive-behavioral therapy; FSS, Fatigue Severity
Scale; PSQI, Pittsburgh Sleep Quality Index.
Data are expressed as mean (s.e.). Data were analyzed using ANCOVA.
Table 4 | Changes in plasma levels of secondary outcomes
during the 6-week trial
CBT group (N=37) Control group (N=35) P-value
Dhs-CRP (%) 27.5 (52.1, 3.13) 3.9 (10.4, 13.7) 0.001
DIL-1b (%) 11.3 (27.9, 1.2) 0.1 (7.2, 10.5) 0.078
DIL-18 (%) 8.4 (26.5, 4.6) 14.1 (1.5, 25.5) o0.001
DoxLDL (%) 5.1 (13.3, 0.6) 26.9 (3.8, 30.9) o0.001
Abbreviations: CBT, cognitive-behavioral therapy; hs-CRP, high-sensitive C-reactive
protein; IL-1b, interleukin 1 beta; IL-18, interleukin 18; oxLDL, oxidized low-density
lipoprotein.
The difference (D) was defined as 100% (post-intervention datapre-intervention
data)/pre-intervention data.
Data are expressed as median (quartiles).
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problems. Figure 1 shows recruitment numbers, exclusions, refusal,
and dropouts throughout the study. After randomization, three
participants in the CBT group and five participants in the control
group refused to participate and withdrew their informed consent
because of personal considerations. Therefore, a total of 72 subjects
(37 in the CBT group and 35 in the control group) participated.
All of the patients had been receiving maintenance HD for
46 months and were recruited at the Far Eastern Memorial
Hospital between July and October 2009. The trial was initiated on
16 November 2009 and ended on 26 December 2009. The study
patients received 3.5–5 h of HD three times a week with a blood flow
rate of 250–300ml/min and dialysate flow of 500–800ml/min, using
bicarbonate dialysate and reverse osmosis-purified water. All of the
participants used high-flux polysulfone membrane as the dialyzer.
The hospital’s Institutional Review Board approved of the study and
all of the participants provided written informed consent.
Interventions: CBT
Participants were assigned to either an intervention group or a
control group. The intervention group received 30-min tri-weekly
treatment sessions of CBT and sleep hygiene education during the
6-week period.21,37 The CBT included a psychiatrist-oriented, video-
assisted CBT program during HD sessions, and group discussion
and education after HD sessions. The cognitive components of the
CBT were designed to assist participants in identifying, challenging,
and changing the misconceptions about sleep. The behavioral
components involved: (1) sleep restriction, which instructed
participants to keep strict schedules of sleep and rising times,
restrict bedtime to be closer to actual sleeping time, and synchronize
the endogenous circadian rhythm and sleep drive; (2) stimulus
control, which helped participants learn to interrupt associations
between sleep, sleep environment, and wakefulness, and to eliminate
activities incompatible with sleep in the bedroom; and (3) relaxation
training, which asked participants to relieve muscular tension,
perform rhythmic breathing, and mental focusing by daily exercise.
The CBT was performed by two psychiatrists with extensive
specialized training in CBT and one assistant psychologist who
had performed CBT for 410 years.
The control group did not receive CBT and only received sleep
hygiene education during the 6-week trial. Every participant in the
control group received sleep problem consultations given by the
psychiatrist or assistant psychologist at least once per week or as
long as the participants needed during the trial.
All participants received sleep hygiene education, which taught
them to better understand the impact of lifestyle habits and
environmental factors on sleep quality during the first week of
trial. Participants who received hypnotics chronically (stable dose
43 months) before being recruited were maintained at the same
dose of hypnotics during the therapy.
Outcomes
Primary outcomes were the efficacy of the 6-week CBTon quality of
sleep. Secondary outcomes were measurements of changes in
inflammatory markers (hs-CRP, IL-1b, and IL-18) and the marker
of oxidative stress (oxLDL) during therapy. In addition, we also
assessed the impact of CBT on the severity of fatigue, depression,
and anxiety. The primary outcomes with respect to efficacy of CBT
were assessed with the PSQI, which includes 7 indices: subjective
sleep quality, latency (time required to fall asleep, converted to a
score of 0–3), duration (actual sleep hours per night, converted to a
score of 0–3), efficiency (total sleep time divided by time in bed,
converted to a score of 0–3), and disturbances (for example, midnight
wake-up, pain, and nightmare), use of sleep medication (frequency of
use of hypnotics per week), and daytime dysfunction (for example,
daytime sleepiness, loss of enthusiasm). The total score ranged from
0 to 21 points, with higher scores meaning poorer sleep quality.38
Secondary outcomes were alterations in inflammatory markers
including hs-CRP, IL-1b, IL-18, selected based on previous
observatory and interventional studies,8,10 and the marker of
oxidative stress, oxLDL14 levels during the trial in all of the
participants. All markers were measured before and after the 6-week
trial under similar conditions.
We assessed the efficacy of CBT on the severity of fatigue,
depression, and anxiety by the FSS, the BDI, and the BAI,
respectively. The FSS is a nine-item instrument that quantifies an
individual’s severity of fatigue based on the tendency to be fatigued
in daily situations.39 Participants were asked to rate on a scale of
1–7 how likely fatigue influenced their daily activities in 9 situations.
An average score 44 indicated a high fatigue severity.
The BDI is a 21-question multiple-choice self-report inventory
for measuring the severity of depression. It is composed of items
relating to symptoms of depression, cognitions, and physical
symptoms. The total score ranges from 0 to 63 points, with higher
total scores indicating more severe depressive symptoms.40
The BAI consists of 21 questions about how the subject has been
feeling in the last week, expressed as common symptoms of anxiety.
Each question has the same set of four possible answer choices. The
total score ranges from 0 to 63 points, with higher scores meaning
more anxiety.41
The PSQI, FSS, BDI, and BAI are well validated and have been
shown to have good reliability and internal consistency.40–43 The
four measurements were completed before and after the 6-week trial
by all of the participants in both groups.
Laboratory measurements
Blood samples for measurements were drawn in the morning, after
an overnight fast of 48 h before the patient’s mid-week dialysis.
Biochemistry data were determined using a Hitachi 747 auto-
analyzer (Hitachi, Tokyo, Japan). The Kt/Vurea and normalized
protein catabolic rate were calculated using a single-compartment
model. hs-CRP levels were assayed by an image autoanalyzer using
the nephelometric method (Beckman Coulter, Fullerton, CA).
Plasma IL-1b and IL-18 levels were measured by ELISA (enzyme-
linked immunosorbent assay) (Biosource, Nivellas, Belgium).
Plasma oxLDL concentrations were measured using a mAb-4E6-
based ELISA (product no. 10-1158-01; Mercodia, Uppsala, Sweden).
Sample size
The priori power analyses were based on the assessment of: (1) the
efficacy of psychological interventions for sleep disturbance from
four randomized control studies yielding effect sizes varying from
0.6 on improvement in anxiety30 to 0.9 on improvement in sleep
variables with pharmacological treatment;23 and (2) changes in
the proinflammatory cytokines IL-1b and IL-18 among dialysis
patients with sleep disturbances yielding an effect size of 0.55
(185±340 pg/ml)9,10 to 0.67 (0.29±0.43 pg/ml).10 On the basis of
these analyses, our predetermined total sample size ranged from
38 to 104 participants, which was sufficient to provide480% power
at P¼ 0.05 (two-tailed) to detect the interventional effects in this
study. The final sample size (N¼ 72) with an expected effect size of
0.55–0.9 was sufficient to accommodate a 20% attrition rate and to
also detect interventional effects.
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Randomization
This study was an open-labeled design. We randomized participants
by computer-generated random numbers with an allocation ratio of
1:1; that is, either to the CBT group or to the control group.
Participants were informed of their allocation sequence by the
nursing staff, and the sequence was concealed until the interventions
were assigned. The generation of allocation sequence and assign-
ment of participants was performed by the project director.
Statistical methods
Continuous data were presented as mean (s.d.), whereas categorical
data were reported as percentages. Medians and quartiles were
displayed for nonparametric data. The Kolmogorov–Smirnov test
and Q–Q plots were used to assess the normal distribution of data.
The results showed that the distributions of PSQI, FSS, BDI, and
BAI in our subjects were normal (all Po0.05). The differences in
demographic characteristics, primary and secondary outcomes,
and other measurements between the participants of the CBT and
control groups were compared using Student’s t-test and the
Wilcoxon signed-rank test. The unadjusted differences in pre- and
post-trial data of outcomes in both groups were compared using
paired Student’s t-test and Mann–Whitney U-test. With regard to
the interventional effect, the post-trial PSQI, FSS, BDI, and BAI
scores between the two groups were compared using ANCOVA
(analysis of covariance). We selected pre-trial PSQI, FSS, BDI, and
BAI as covariates and treatment (CBTor control) as the fixed factor,
and the data were presented as mean (s.e.). Otherwise, the data of
the secondary outcomes were analyzed with nonparametric
methods. Therefore, differences of pre- and post-trial data (D) of
secondary outcomes in both groups were compared using the
Mann–Whitney U-test. All statistical analyses were performed
using SPSS software, version 17.0 (SPSS, Chicago, IL). Two-sided
P-values o0.05 were considered statistically significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This study was supported by grants from the Far Eastern Memorial
Hospital (FEMH-97-D-039), Taiwan. We express our thanks to the Ta-
Tung Kidney Foundation and to Hsin-Chin Lee Kidney Research Fund
for supporting this investigation.
REFERENCES
1. Chen WC, Lim PS, Wu WC et al. Sleep behavior disorders in a large cohort
of Chinese (Taiwanese) patients maintained by long-term hemodialysis.
Am J Kidney Dis 2006; 48: 277–284.
2. Merlino G, Piani A, Dolso P et al. Sleep disorders in patients with end-
stage renal disease undergoing dialysis therapy. Nephrol Dial Transplant
2006; 21: 184–190.
3. Meier-Ewert HK, Ridker PM, Rifai N et al. Effect of sleep loss on C-reactive
protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol
2004; 43: 678–683.
4. Patel SR, Zhu X, Storfer-Isser A et al. Sleep duration and biomarkers of
inflammation. Sleep 2009; 32: 200–204.
5. Vgontzas AN, Zoumakis E, Bixler EO et al. Adverse effects of modest sleep
restriction on sleepiness, performance, and inflammatory cytokines.
J Clin Endocrinol Metab 2004; 89: 2119–2126.
6. Opp MR. Cytokines and sleep. Sleep Med Rev 2005; 9: 355–364.
7. Kubota T, Fang J, Brown RA et al. Interleukin-18 promotes sleep in
rabbits and rats. Am J Physiol Regul Integr Comp Physiol 2001; 281:
R828–R838.
8. Chiu YL, Chuang YF, Fang KC et al. Higher systemic inflammation is
associated with poorer sleep quality in stable haemodialysis patients.
Nephrol Dial Transplant 2009; 24: 247–251.
9. Yang JY, Huang JW, Chiang CK et al. Higher plasma interleukin-18 levels
associated with poor quality of sleep in peritoneal dialysis patients.
Nephrol Dial Transplant 2007; 22: 3606–3609.
10. Chen HY, Chiang CK, Wang HH et al. Cognitive-behavioral therapy
for sleep disturbance in patients undergoing peritoneal dialysis:
a pilot randomized controlled trial. Am J Kidney Dis 2008; 52:
314–323.
11. Bayes B, Pastor MC, Bonal J et al. Oxidative stress, inflammation and
cardiovascular mortality in haemodialysis—role of seniority and
intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial
Transplant 2006; 21: 984–990.
12. Dursun B, Dursun E, Suleymanlar G et al. Carotid artery intima-media
thickness correlates with oxidative stress in chronic haemodialysis
patients with accelerated atherosclerosis. Nephrol Dial Transplant 2008;
23: 1697–1703.
13. Krasniak A, Drozdz M, Pasowicz M et al. Factors involved in vascular
calcification and atherosclerosis in maintenance haemodialysis patients.
Nephrol Dial Transplant 2007; 22: 515–521.
14. Bayes B, Pastor MC, Bonal J et al. Homocysteine, C-reactive protein,
lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial
Transplant 2003; 18: 106–112.
15. Miyazaki H, Matsuoka H, Itabe H et al. Hemodialysis impairs endothelial
function via oxidative stress: effects of vitamin E-coated dialyzer.
Circulation 2000; 101: 1002–1006.
16. Everson CA, Laatsch CD, Hogg N. Antioxidant defense responses to
sleep loss and sleep recovery. Am J Physiol Regul Integr Comp Physiol
2005; 288: R374–R383.
17. Novak M, Mendelssohn D, Shapiro CM et al. Diagnosis and management
of sleep apnea syndrome and restless legs syndrome in dialysis patients.
Semin Dial 2006; 19: 210–216.
18. Bradley TD, Floras JS. Obstructive sleep apnoea and its cardiovascular
consequences. Lancet 2009; 373: 82–93.
19. Lavie L. Obstructive sleep apnoea syndrome—an oxidative stress
disorder. Sleep Med Rev 2003; 7: 35–51.
20. Svatikova A, Wolk R, Lerman LO et al. Oxidative stress in obstructive sleep
apnoea. Eur Heart J 2005; 26: 2435–2439.
21. Jacobs GD, Pace-Schott EF, Stickgold R et al. Cognitive behavior therapy
and pharmacotherapy for insomnia: a randomized controlled trial and
direct comparison. Arch Intern Med 2004; 164: 1888–1896.
22. Edinger JD, Wohlgemuth WK, Radtke RA et al. Cognitive behavioral
therapy for treatment of chronic primary insomnia: a randomized
controlled trial. JAMA 2001; 285: 1856–1864.
23. Sivertsen B, Omvik S, Pallesen S et al. Cognitive behavioral therapy vs
zopiclone for treatment of chronic primary insomnia in older adults:
a randomized controlled trial. JAMA 2006; 295: 2851–2858.
24. Duarte PS, Miyazaki MC, Blay SL et al. Cognitive-behavioral group therapy
is an effective treatment for major depression in hemodialysis patients.
Kidney Int 2009; 76: 414–421.
25. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role
of cytokines in the pathophysiology of major depression. Biol Psychiatry
2009; 65: 732–741.
26. Montgomery P, Dennis J. Cognitive behavioural interventions for sleep
problems in adults aged 60+. Cochrane Database Systematic Review
2003: Article number CD003161.
27. Cohen L, Warneke C, Fouladi RT et al. Psychological adjustment
and sleep quality in a randomized trial of the effects of a Tibetan
yoga intervention in patients with lymphoma. Cancer 2004; 100:
2253–2260.
28. Li F, Fisher KJ, Harmer P et al. Tai chi and self-rated quality of sleep
and daytime sleepiness in older adults: a randomized controlled trial.
J Am Geriatr Soc 2004; 52: 892–900.
29. Morin CM, Vallieres A, Guay B et al. Cognitive behavioral therapy, singly
and combined with medication, for persistent insomnia: a randomized
controlled trial. JAMA 2009; 301: 2005–2015.
30. Stanley MA, Wilson NL, Novy DM et al. Cognitive behavior therapy for
generalized anxiety disorder among older adults in primary care: a
randomized clinical trial. JAMA 2009; 301: 1460–1467.
31. Elenkov IJ, Iezzoni DG, Daly A et al. Cytokine dysregulation, inflammation
and well-being. Neuroimmunomodulation 2005; 12: 255–269.
32. Opp MR, Krueger JM. Anti-interleukin-1 beta reduces sleep and sleep
rebound after sleep deprivation in rats. Am J Physiol 1994; 266:
R688–R695.
33. Gritters M, Grooteman MP, Schoorl M et al. Citrate anticoagulation
abolishes degranulation of polymorphonuclear cells and platelets and
reduces oxidative stress during haemodialysis. Nephrol Dial Transplant
2006; 21: 153–159.
Kidney International (2011) 80, 415–422 421
H-Y Chen et al: CBT for HD patients with insomnia o r ig ina l a r t i c l e
34. Meier P, Spertini F, Blanc E et al. Oxidized low-density lipoproteins
activate CD4+ T cell apoptosis in patients with end-stage renal disease
through Fas engagement. J Am Soc Nephrol 2007; 18: 331–342.
35. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes
in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960–1966.
36. Guilleminault C, Davis K, Huynh NT. Prospective randomized study of
patients with insomnia and mild sleep disordered breathing. Sleep 2008;
31: 1527–1533.
37. Jacobs GD, Benson H, Friedman R. Perceived benefits in a behavioral-
medicine insomnia program: a clinical report. Am J Med 1996; 100:
212–216.
38. Buysse DJ, Reynolds III CF, Monk TH et al. The Pittsburgh Sleep Quality
Index: a new instrument for psychiatric practice and research. Psychiatry
Res 1989; 28: 193–213.
39. Krupp LB, LaRocca NG, Muir-Nash J et al. The fatigue severity scale.
Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol 1989; 46: 1121–1123.
40. Watnick S, Wang PL, Demadura T et al. Validation of 2 depression
screening tools in dialysis patients. Am J Kidney Dis 2005; 46: 919–924.
41. Luo N, Fones CS, Thumboo J et al. Factors influencing health-related
quality of life of Asians with anxiety disorders in Singapore. Qual Life Res
2004; 13: 557–565.
42. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson’s
disease—the Fatigue Severity Scale. Eur J Neurol 2002; 9: 595–600.
43. Tsai PS, Wang SY, Wang MY et al. Psychometric evaluation of the
Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in
primary insomnia and control subjects. Qual Life Res 2005; 14:
1943–1952.
422 Kidney International (2011) 80, 415–422
or ig ina l a r t i c l e H-Y Chen et al: CBT for HD patients with insomnia
